Company news
Scisparc Ltd. (NASDAQ:SPRC) news
Scisparc Ltd. news releases on 6ix. Latest, May 27, 2025: SciSparc Announces Publication of Japanese Patent Application
Press releases — page 2
SciSparc Announces Publication of Japanese Patent Application
May 27, 2025
SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction
May 12, 2025
Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction
May 12, 2025
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
April 25, 2025
SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea
March 10, 2025
SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers
March 3, 2025
SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax’s Entry into Direct Import of JAC Electric Vehicles
February 27, 2025
SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology
February 18, 2025
SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico
February 3, 2025
SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
January 14, 2025
SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results
January 6, 2025
SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
January 5, 2025
SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder
December 30, 2024
SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company
December 15, 2024
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment
September 29, 2024
SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX
September 25, 2024
SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment
September 22, 2024
SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment
September 17, 2024
SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy
September 15, 2024
SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax’s Direct Import Agreement with Major Chinese Vehicle Manufacturer
September 10, 2024
SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome
August 22, 2024
SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board
August 21, 2024
SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment
August 18, 2024
SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million
August 15, 2024
SciSparc Updates Regarding the Status of the AutoMax Merger
August 13, 2024
SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million
July 16, 2024
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
July 15, 2024
SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
July 15, 2024
SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company
July 7, 2024
SciSparc Secures Strategic Advantage with Grant of European Patent
May 30, 2024
SciSparc to Acquire AutoMax
April 10, 2024
SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression
March 26, 2024
SciSparc Granted Another Patent, Strengthening its Core Technology in Canada
March 17, 2024
SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial
March 13, 2024
SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder
March 7, 2024
SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe
March 6, 2024
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
March 5, 2024
SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing
February 28, 2024
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
February 26, 2024
SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
January 28, 2024
SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement
January 23, 2024
SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 million
January 18, 2024
SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform
December 12, 2023
SciSparc Provides Updates Regarding the Non-Binding Letter of Intent to Acquire Leading Vehicle Importer Company in Israel
December 6, 2023
SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment
November 27, 2023
SciSparc Adopts Limited Duration Shareholder Rights Plan
November 27, 2023
SciSparc Signs Non-Binding Letter of Intent to Merge with Leading Vehicle Importer Company in Israel
November 21, 2023
SciSparc Aims to Change Tourette Syndrome Treatments; Will Start a Phase IIb Trial with its Innovative Pharma-Grade THC-Based Medication
November 9, 2023
SciSparc Granted Patent from the Australian Patent Office for its Reduction of Opioids Use in Pain Management Technology
October 30, 2023
SciSparc Granted Patent for its Core Technology From the Australian Patent Office
October 23, 2023